H.C. Wainwright lowered the firm’s price target on AC Immune (ACIU) to $12 from $16 and keeps a Buy rating on the shares. The interim 26-week data from the ACI-7104.056 VacSYn Phase 2 trial showed that the vaccine continues to be safe, the analyst tells investors in a research note. The firm updated the stock’s discount rate to better reflect the current macro environment for Smid-cap biotech companies.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACIU: